1887

Abstract

SUMMARY

Mice with established herpes encephalitis were used to compare the effects of chemotherapy using three different nucleoside analogues. Encephalitis was produced by intranasal inoculation of a type 1 strain of herpes simplex virus. Without chemotherapy all mice died within 5 to 7 days of inoculation. Oral acyclovir (ACV) was a successful preventative measure if commenced within 2 days of inoculation but much less effective if the onset of treatment was further delayed. From the third day, when central nervous system infection had definitely become established, ACV only reduced mortality if given intraperitoneally (i.p.) at regular 6-hourly intervals. Comparison with bromovinyldeoxyuridine (BVdU) and the new nucleoside analogue dihydroxypropoxy-methylguanine (DHPG) using the same 6-hourly i.p. regimen revealed that BVdU was poorly effective, despite better activity , whereas DHPG was the most successful. Virus was rapidly eradicated from all parts of the brain by DHPG therapy, and by day 10, no infectious virus remained in the brains of treated mice, no virus antigens were observed and no trace of virus DNA could be detected in neural tissues by Southern blotting.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-65-4-707
1984-04-01
2022-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/65/4/JV0650040707.html?itemId=/content/journal/jgv/10.1099/0022-1317-65-4-707&mimeType=html&fmt=ahah

References

  1. Anderson J. R., Field H. J. 1983; The distribution of herpes simplex type 1 antigen in mouse central nervous system after different routes of inoculation. Journal of Neurological Sciences 60:181–195
    [Google Scholar]
  2. Ashton W. T., Karkas J. D., Field A. K., Tolman R. L. 1982; Activation by thymidine kinase and potent anti-herpetic activity of 2′-nor-2′-deoxyguanosine (2′-NDG). Biochemical and Biophysical Research Communications 108:1718–1721
    [Google Scholar]
  3. Biron K. K., Noglin J. E., De Miranda P., Elion G. B. 1982; Uptake, distribution and anabolism of acyclovir in herpes simplex virus infected mice. Antimicrobial Agents and Chemotherapy 21:44–50
    [Google Scholar]
  4. Dayan A. D., Gooddy W., Harrison M. J. G., Rudge P. 1972; Brain stem encephalitis caused by herpes virus hominis. British Medical Journal ii:405–406
    [Google Scholar]
  5. Declercq E., Luczak M. 1975; Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs. Journal of Infectious Diseases 133: supplement A226–235
    [Google Scholar]
  6. Declercq E., Descamps U., De Somer P., Barr P. J., Jones A. S., Walker R. T. 1979; Pharmokinetics of E-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrobial Agents and Chemotherapy 16:234–236
    [Google Scholar]
  7. DE Clercq E., Zhang Z.-X., Sim I. S. 1982; Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrobial Agents and Chemotherapy 22:421–425
    [Google Scholar]
  8. DE Miranda P., Krasny H. C., Page D. A., Elion G. B. 1982; Species differences in the disposition of acyclovir. American Journal of Medicine 73:31–35
    [Google Scholar]
  9. Esiri M. M. 1982; Herpes simplex encephalitis – an immunohistological study of the distribution of viral antigen within the brain. Journal of Neurological Sciences 54:209–266
    [Google Scholar]
  10. Field H. J., DE Clercq E. 1981; Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. Journal of General Virology 56:259–265
    [Google Scholar]
  11. Field H. J., Neden J. 1982; Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir. Antiviral Research 2:243–254
    [Google Scholar]
  12. Field H. J., Wildy P. 1978; The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. Journal of Hygiene 81:267–277
    [Google Scholar]
  13. Field H. J., Bell S. E., Elion G. B., Nash A. A., Wildy P. 1979; Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrobial Agents and Chemotherapy 15:554–561
    [Google Scholar]
  14. Glazko A. J., Chang T., Drach J. C. 1975; Species differences in the metabolic disposition of adenine arabinoside. In Adenine Arabinoside: an Antiviral Agent pp 111–113 Edited by Pavan-Langston D. Buchanan R. A., Alford C. A. Jr New York: Raven Press;
    [Google Scholar]
  15. Hill T. J., Field H. J., Blyth W. A. 1975; Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28:341–353
    [Google Scholar]
  16. Kern E. R., Richards J. T., Glasgow L. A., Overall J. C., DE Miranda P. 1982; Optimal treatment of herpes simplex virus encephalitis in mice with oral acyclovir. American Journal of Medicine 73:125–131
    [Google Scholar]
  17. Larsson A., Braunstrom G., Oberg B. 1983; Reversal of the antiherpes activity of nucleoside analogues: a kinetic analysis in cell culture. Antimicrobial Agents and Chemotherapy (in press)
    [Google Scholar]
  18. Mims C. A. 1960; Intracerebral infections and the growth of viruses in the mouse brain. British Journal of Experimental Pathology 41:52–59
    [Google Scholar]
  19. Park N.-H., Pavan-Langston D., McLean S. L., Albert D. M. 1979; Therapy of experimental herpes simplex encephalitis with acyclovir in mice. Antimicrobial Agents and Chemotherapy 15:775–779
    [Google Scholar]
  20. Reefschlager J., Wutzler P., Thiel K.-D., Barwolff D., Langen P., Sprossig M., Rosenthal H. A. 1982; Efficacy of (E)-5-(2-bromovinyl)-l-deoxyuridine against experimental herpes encephalitis in mice. Antiviral Research 2:255–265
    [Google Scholar]
  21. Rigby P. W. J., Dieckmann M., Rhodes C., Berg P. 1977; Labelling DNA to high specific activity in vitro by nick translation with DNA polymerase I. Journal of Molecular Biology 113:237–251
    [Google Scholar]
  22. Rock D. L., Fraser N. W. 1983; Detection of HSV-1 genome in central nervous system of latently infected mice. Nature, London 302:523–525
    [Google Scholar]
  23. Schaeffer H. J., Beauchamp L., De Miranda P., Elion G. B., Bauer D. J., Collins P. 1978; 9-(2)Hydroxy-ethoxymethyl)guanine activity against viruses of the herpes group. Nature, London 272:583–585
    [Google Scholar]
  24. Schinazi R. F., Peters J., Sokol M. K., Nahmias A. J. 1983; Therapeutic activities of l-(2)fluoro-2′-deoxy-β-d-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrobial Agents and Chemotherapy 24:95–103
    [Google Scholar]
  25. Southern E. M. 1975; Detection of specific sequences among DNA fragments separated by gel electrophoresis. Journal of Molecular Biology 98:503–517
    [Google Scholar]
  26. Wagner M. J., Summers W. C. 1978; Structure of the joint region and the termini of the DNA of herpes simplex virus type 1. Journal of Virology 27:374–387
    [Google Scholar]
  27. Whitley R. J. 1983; Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections: vidarabin versus acyclovir. Journal of Antimicrobial Chemotherapy 12: supplement B105–112
    [Google Scholar]
  28. Whitley R. J., Soong S. J., Dolin R., Galasso G. J., Ch’ien L. T., Alford C. A. The Collaborative Study Group 1977; Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. New England Journal of Medicine 297:289–294
    [Google Scholar]
  29. Whitley R. J., Soong S. J., Hirsch M. S. 1981; Herpes simplex encephalitis. Vidarabin therapy and diagnostic problems. New England Journal of Medicine 304:313–318
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-65-4-707
Loading
/content/journal/jgv/10.1099/0022-1317-65-4-707
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error